| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications | 59 | 2024 | 2947 | 4.920 |
Why?
|
| Antipsychotic Agents | 32 | 2024 | 3067 | 4.530 |
Why?
|
| Hot Flashes | 36 | 2020 | 330 | 4.480 |
Why?
|
| Abnormalities, Drug-Induced | 15 | 2023 | 339 | 4.030 |
Why?
|
| Depression, Postpartum | 19 | 2023 | 346 | 3.390 |
Why?
|
| Antidepressive Agents | 46 | 2024 | 2897 | 3.090 |
Why?
|
| Menopause | 28 | 2020 | 1646 | 2.850 |
Why?
|
| Puerperal Disorders | 17 | 2024 | 299 | 2.400 |
Why?
|
| Premenstrual Syndrome | 19 | 2017 | 109 | 2.280 |
Why?
|
| Depressive Disorder, Major | 28 | 2024 | 4761 | 2.230 |
Why?
|
| Depressive Disorder | 41 | 2023 | 3728 | 2.150 |
Why?
|
| Pregnancy | 114 | 2024 | 29874 | 2.130 |
Why?
|
| Estradiol | 19 | 2020 | 1937 | 2.130 |
Why?
|
| Perimenopause | 16 | 2020 | 142 | 2.020 |
Why?
|
| Registries | 21 | 2024 | 8224 | 1.970 |
Why?
|
| Cyclohexanols | 8 | 2015 | 126 | 1.950 |
Why?
|
| Prenatal Exposure Delayed Effects | 13 | 2024 | 2518 | 1.650 |
Why?
|
| Psychotic Disorders | 16 | 2024 | 3223 | 1.510 |
Why?
|
| Psychotropic Drugs | 8 | 2019 | 888 | 1.400 |
Why?
|
| Estrogen Replacement Therapy | 16 | 2018 | 1208 | 1.330 |
Why?
|
| Depression | 30 | 2023 | 8124 | 1.310 |
Why?
|
| Mood Disorders | 11 | 2010 | 1127 | 1.280 |
Why?
|
| Postpartum Period | 14 | 2024 | 1173 | 1.270 |
Why?
|
| Ultrasonography, Prenatal | 9 | 2016 | 1755 | 1.260 |
Why?
|
| Antidepressive Agents, Second-Generation | 8 | 2018 | 489 | 1.250 |
Why?
|
| Postmenopause | 20 | 2018 | 2513 | 1.150 |
Why?
|
| Mental Disorders | 16 | 2023 | 6845 | 1.130 |
Why?
|
| Pregnancy Outcome | 13 | 2023 | 2921 | 1.120 |
Why?
|
| Citalopram | 8 | 2015 | 402 | 1.050 |
Why?
|
| Climacteric | 6 | 2003 | 57 | 0.990 |
Why?
|
| Hospitals, General | 7 | 2024 | 798 | 0.970 |
Why?
|
| Benzodiazepines | 5 | 2022 | 1132 | 0.960 |
Why?
|
| Female | 237 | 2024 | 392644 | 0.950 |
Why?
|
| Psychiatric Status Rating Scales | 33 | 2021 | 6019 | 0.890 |
Why?
|
| Menstrual Cycle | 8 | 2007 | 539 | 0.880 |
Why?
|
| Central Nervous System Stimulants | 2 | 2023 | 1177 | 0.870 |
Why?
|
| Bipolar Disorder | 22 | 2019 | 5092 | 0.860 |
Why?
|
| Infertility, Female | 4 | 2018 | 760 | 0.850 |
Why?
|
| Vasomotor System | 6 | 2020 | 207 | 0.850 |
Why?
|
| Postpartum Hemorrhage | 2 | 2024 | 271 | 0.840 |
Why?
|
| Paroxetine | 4 | 2008 | 182 | 0.830 |
Why?
|
| Pregnancy Trimester, First | 9 | 2023 | 907 | 0.820 |
Why?
|
| Adult | 154 | 2024 | 221177 | 0.770 |
Why?
|
| Fetal Heart | 3 | 2015 | 281 | 0.720 |
Why?
|
| Fatty Acids, Omega-3 | 9 | 2015 | 1390 | 0.710 |
Why?
|
| Massachusetts | 12 | 2024 | 8830 | 0.710 |
Why?
|
| Uterus | 3 | 2013 | 649 | 0.690 |
Why?
|
| Fluoxetine | 10 | 2005 | 733 | 0.680 |
Why?
|
| Humans | 246 | 2024 | 761504 | 0.670 |
Why?
|
| Leiomyoma | 4 | 2013 | 636 | 0.650 |
Why?
|
| Ultrasonography, Doppler, Color | 4 | 2007 | 231 | 0.640 |
Why?
|
| Methylphenidate | 1 | 2023 | 488 | 0.640 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 10 | 2020 | 1081 | 0.640 |
Why?
|
| Tetrahydrofolates | 1 | 2019 | 58 | 0.630 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2023 | 3708 | 0.620 |
Why?
|
| Piperazines | 4 | 2018 | 2523 | 0.590 |
Why?
|
| Reproduction | 4 | 2018 | 645 | 0.590 |
Why?
|
| Mass Screening | 8 | 2023 | 5428 | 0.590 |
Why?
|
| Dietary Supplements | 6 | 2019 | 3415 | 0.580 |
Why?
|
| Ethinyl Estradiol | 4 | 2017 | 113 | 0.580 |
Why?
|
| Anxiety | 10 | 2024 | 4573 | 0.560 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2017 | 103 | 0.560 |
Why?
|
| Estrogens | 10 | 2018 | 1522 | 0.560 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2019 | 625 | 0.560 |
Why?
|
| Anxiety Disorders | 12 | 2013 | 2720 | 0.550 |
Why?
|
| Sulfides | 1 | 2017 | 169 | 0.550 |
Why?
|
| Antimanic Agents | 7 | 2019 | 520 | 0.540 |
Why?
|
| Thiophenes | 2 | 2013 | 569 | 0.520 |
Why?
|
| Drug Labeling | 1 | 2018 | 248 | 0.520 |
Why?
|
| Affect | 10 | 2020 | 1486 | 0.510 |
Why?
|
| Uterine Neoplasms | 4 | 2013 | 1420 | 0.490 |
Why?
|
| Psychotherapy | 7 | 2003 | 1647 | 0.480 |
Why?
|
| Diabetes, Gestational | 3 | 2023 | 1248 | 0.480 |
Why?
|
| Breast Feeding | 10 | 2024 | 1359 | 0.470 |
Why?
|
| Eicosapentaenoic Acid | 2 | 2015 | 561 | 0.470 |
Why?
|
| Lithium | 9 | 2008 | 596 | 0.460 |
Why?
|
| Prospective Studies | 29 | 2023 | 54425 | 0.460 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2010 | 607 | 0.460 |
Why?
|
| Premenopause | 5 | 2007 | 1039 | 0.450 |
Why?
|
| Prenatal Care | 2 | 2019 | 1139 | 0.450 |
Why?
|
| Fertilization | 2 | 2014 | 199 | 0.450 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2018 | 497 | 0.450 |
Why?
|
| Lithium Compounds | 3 | 2017 | 223 | 0.440 |
Why?
|
| Docosahexaenoic Acids | 3 | 2015 | 908 | 0.440 |
Why?
|
| Suicidal Ideation | 2 | 2023 | 1447 | 0.440 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2018 | 589 | 0.440 |
Why?
|
| Middle Aged | 91 | 2022 | 220895 | 0.430 |
Why?
|
| Suicide | 2 | 2023 | 1601 | 0.420 |
Why?
|
| Trachea | 2 | 2016 | 1089 | 0.410 |
Why?
|
| Premature Birth | 2 | 2023 | 1782 | 0.410 |
Why?
|
| Heart Defects, Congenital | 7 | 2017 | 4671 | 0.410 |
Why?
|
| Hypnotics and Sedatives | 3 | 2011 | 1179 | 0.400 |
Why?
|
| Azabicyclo Compounds | 2 | 2009 | 68 | 0.400 |
Why?
|
| Double-Blind Method | 27 | 2017 | 12341 | 0.400 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 293 | 0.400 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2016 | 1148 | 0.400 |
Why?
|
| Androstenes | 2 | 2017 | 181 | 0.400 |
Why?
|
| Yoga | 6 | 2015 | 281 | 0.400 |
Why?
|
| Withholding Treatment | 2 | 2014 | 617 | 0.390 |
Why?
|
| Obsessive-Compulsive Disorder | 5 | 2024 | 1491 | 0.380 |
Why?
|
| Treatment Refusal | 2 | 2004 | 429 | 0.370 |
Why?
|
| Transposition of Great Vessels | 1 | 2015 | 581 | 0.370 |
Why?
|
| Young Adult | 26 | 2024 | 59243 | 0.370 |
Why?
|
| Vagina | 6 | 2018 | 838 | 0.360 |
Why?
|
| Follicle Stimulating Hormone | 5 | 2011 | 726 | 0.360 |
Why?
|
| Infant, Newborn | 24 | 2023 | 26198 | 0.360 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2010 | 36 | 0.360 |
Why?
|
| Cesarean Section | 2 | 2018 | 1396 | 0.360 |
Why?
|
| Treatment Outcome | 40 | 2020 | 64680 | 0.350 |
Why?
|
| Panic Disorder | 5 | 2001 | 613 | 0.340 |
Why?
|
| Parturition | 3 | 2023 | 445 | 0.340 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 1664 | 0.340 |
Why?
|
| Recurrence | 17 | 2018 | 8465 | 0.330 |
Why?
|
| Severity of Illness Index | 22 | 2019 | 15842 | 0.330 |
Why?
|
| Pre-Eclampsia | 2 | 2018 | 1231 | 0.330 |
Why?
|
| Image Enhancement | 4 | 2010 | 2885 | 0.320 |
Why?
|
| Vaginal Diseases | 3 | 2020 | 103 | 0.320 |
Why?
|
| Sleep | 7 | 2014 | 4768 | 0.310 |
Why?
|
| Placebos | 9 | 2014 | 1667 | 0.310 |
Why?
|
| Hypercholesterolemia | 1 | 2015 | 1141 | 0.310 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2011 | 4063 | 0.300 |
Why?
|
| Single-Blind Method | 6 | 2021 | 1572 | 0.300 |
Why?
|
| Stress, Psychological | 3 | 2021 | 4481 | 0.300 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 1702 | 0.300 |
Why?
|
| Ovarian Neoplasms | 5 | 2007 | 4876 | 0.290 |
Why?
|
| Menstruation Disturbances | 2 | 2006 | 143 | 0.290 |
Why?
|
| Adolescent | 30 | 2022 | 88319 | 0.290 |
Why?
|
| Vitamins | 1 | 2015 | 1635 | 0.280 |
Why?
|
| Clonazepam | 7 | 2001 | 135 | 0.280 |
Why?
|
| Ovarian Cysts | 1 | 2007 | 108 | 0.280 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2010 | 3357 | 0.280 |
Why?
|
| Anti-Anxiety Agents | 4 | 2024 | 397 | 0.280 |
Why?
|
| Sertraline | 3 | 2003 | 209 | 0.270 |
Why?
|
| Secondary Prevention | 3 | 2019 | 1475 | 0.270 |
Why?
|
| Milk, Human | 3 | 2007 | 486 | 0.270 |
Why?
|
| Outpatients | 1 | 2014 | 1597 | 0.270 |
Why?
|
| Pregnant Women | 3 | 2023 | 566 | 0.270 |
Why?
|
| Cognition | 4 | 2021 | 6990 | 0.260 |
Why?
|
| Fertilization in Vitro | 1 | 2013 | 1292 | 0.250 |
Why?
|
| Maternal-Fetal Exchange | 3 | 2019 | 461 | 0.250 |
Why?
|
| Contraceptives, Oral | 1 | 2007 | 554 | 0.250 |
Why?
|
| Panic | 6 | 1991 | 103 | 0.250 |
Why?
|
| Sudden Infant Death | 1 | 2007 | 292 | 0.240 |
Why?
|
| Pregnancy Trimester, Third | 5 | 2017 | 583 | 0.230 |
Why?
|
| Lactation | 3 | 2021 | 397 | 0.220 |
Why?
|
| Pattern Recognition, Automated | 1 | 2010 | 997 | 0.220 |
Why?
|
| Risk Factors | 32 | 2024 | 74206 | 0.220 |
Why?
|
| Impulsive Behavior | 1 | 2006 | 346 | 0.220 |
Why?
|
| Qualitative Research | 2 | 2024 | 3023 | 0.210 |
Why?
|
| Bupropion | 1 | 2005 | 304 | 0.210 |
Why?
|
| Dibenzothiazepines | 1 | 2003 | 102 | 0.210 |
Why?
|
| Infant | 10 | 2023 | 36192 | 0.210 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2003 | 140 | 0.210 |
Why?
|
| Life Change Events | 3 | 2009 | 952 | 0.200 |
Why?
|
| Sweating | 4 | 2015 | 155 | 0.200 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2014 | 432 | 0.200 |
Why?
|
| Amphetamine | 1 | 2023 | 224 | 0.200 |
Why?
|
| Buspirone | 1 | 2022 | 81 | 0.200 |
Why?
|
| Acetates | 1 | 2003 | 321 | 0.200 |
Why?
|
| Follow-Up Studies | 17 | 2023 | 39106 | 0.200 |
Why?
|
| Anticonvulsants | 7 | 2017 | 1906 | 0.200 |
Why?
|
| Sensitivity and Specificity | 11 | 2016 | 14666 | 0.200 |
Why?
|
| Amines | 1 | 2003 | 281 | 0.200 |
Why?
|
| Vitamin D | 1 | 2015 | 3303 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2016 | 10766 | 0.190 |
Why?
|
| Administration, Cutaneous | 5 | 2011 | 713 | 0.190 |
Why?
|
| Case-Control Studies | 10 | 2021 | 22176 | 0.190 |
Why?
|
| Disease Progression | 1 | 2018 | 13506 | 0.190 |
Why?
|
| Endometriosis | 2 | 2003 | 870 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2013 | 1852 | 0.190 |
Why?
|
| Drug Administration Schedule | 9 | 2005 | 4853 | 0.180 |
Why?
|
| Prevalence | 11 | 2017 | 15732 | 0.180 |
Why?
|
| Valproic Acid | 5 | 2006 | 443 | 0.180 |
Why?
|
| Progesterone | 2 | 2020 | 742 | 0.180 |
Why?
|
| Hormone Replacement Therapy | 2 | 2003 | 751 | 0.180 |
Why?
|
| Endometrium | 3 | 2013 | 403 | 0.180 |
Why?
|
| Fallopian Tubes | 1 | 2001 | 177 | 0.180 |
Why?
|
| Luteinizing Hormone | 1 | 2003 | 820 | 0.170 |
Why?
|
| Tourette Syndrome | 1 | 2003 | 395 | 0.170 |
Why?
|
| Mothers | 3 | 2024 | 2198 | 0.170 |
Why?
|
| Affective Symptoms | 1 | 2002 | 417 | 0.170 |
Why?
|
| Quality of Life | 8 | 2020 | 13367 | 0.170 |
Why?
|
| Feedback | 1 | 2023 | 791 | 0.160 |
Why?
|
| Comorbidity | 10 | 2017 | 10508 | 0.160 |
Why?
|
| Interview, Psychological | 4 | 2017 | 809 | 0.160 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 5 | 2017 | 1988 | 0.160 |
Why?
|
| Perinatal Care | 1 | 2021 | 243 | 0.160 |
Why?
|
| Sodium Chloride | 1 | 2001 | 587 | 0.160 |
Why?
|
| Ultrasonography, Doppler | 1 | 2001 | 462 | 0.160 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2019 | 80 | 0.160 |
Why?
|
| Phobic Disorders | 3 | 1990 | 439 | 0.160 |
Why?
|
| Women's Health | 3 | 2016 | 2065 | 0.160 |
Why?
|
| Exercise | 5 | 2015 | 5890 | 0.150 |
Why?
|
| 1-Naphthylamine | 1 | 1998 | 49 | 0.150 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 2 | 2012 | 64 | 0.150 |
Why?
|
| Prediabetic State | 1 | 2023 | 545 | 0.150 |
Why?
|
| Canada | 1 | 2023 | 2122 | 0.150 |
Why?
|
| Research Design | 6 | 2021 | 6180 | 0.140 |
Why?
|
| Substance-Related Disorders | 3 | 2021 | 4420 | 0.140 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2003 | 1141 | 0.140 |
Why?
|
| Hormones | 1 | 2001 | 869 | 0.140 |
Why?
|
| Pregnancy Trimester, Second | 4 | 2010 | 731 | 0.140 |
Why?
|
| Obesity | 1 | 2019 | 12947 | 0.140 |
Why?
|
| Smoking | 5 | 2009 | 9053 | 0.140 |
Why?
|
| Cohort Studies | 17 | 2017 | 41487 | 0.140 |
Why?
|
| Sexual Dysfunctions, Psychological | 2 | 2016 | 189 | 0.140 |
Why?
|
| Echocardiography | 1 | 2009 | 4989 | 0.130 |
Why?
|
| Gestational Age | 5 | 2014 | 3577 | 0.130 |
Why?
|
| Fertility Agents, Female | 1 | 2016 | 101 | 0.130 |
Why?
|
| Risk Assessment | 11 | 2018 | 23995 | 0.130 |
Why?
|
| Child Development | 3 | 2021 | 2306 | 0.130 |
Why?
|
| Ultrasonography | 8 | 2013 | 5972 | 0.130 |
Why?
|
| Pilot Projects | 7 | 2014 | 8631 | 0.130 |
Why?
|
| Incidence | 8 | 2024 | 21353 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2020 | 10209 | 0.130 |
Why?
|
| Drug Therapy, Combination | 5 | 2017 | 6310 | 0.130 |
Why?
|
| Cross-Sectional Studies | 12 | 2024 | 26125 | 0.120 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 20098 | 0.120 |
Why?
|
| Luteal Phase | 3 | 2006 | 138 | 0.120 |
Why?
|
| Serotonin | 2 | 2006 | 1041 | 0.120 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 5440 | 0.120 |
Why?
|
| Age Factors | 11 | 2006 | 18395 | 0.120 |
Why?
|
| Risk | 6 | 2016 | 9610 | 0.120 |
Why?
|
| Leuprolide | 1 | 2016 | 312 | 0.120 |
Why?
|
| Pregnancy Trimesters | 1 | 2015 | 197 | 0.120 |
Why?
|
| Schizophrenic Psychology | 2 | 2017 | 1647 | 0.120 |
Why?
|
| Fear | 5 | 2009 | 1476 | 0.120 |
Why?
|
| Progesterone Congeners | 1 | 1994 | 44 | 0.120 |
Why?
|
| Forecasting | 1 | 2023 | 2928 | 0.110 |
Why?
|
| Obstetric Labor Complications | 1 | 1996 | 236 | 0.110 |
Why?
|
| Endometrial Neoplasms | 1 | 2003 | 1366 | 0.110 |
Why?
|
| Retrospective Studies | 16 | 2024 | 80636 | 0.110 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2017 | 602 | 0.110 |
Why?
|
| Hospitals, Psychiatric | 1 | 2014 | 321 | 0.110 |
Why?
|
| Ebstein Anomaly | 1 | 1994 | 105 | 0.100 |
Why?
|
| Telephone | 1 | 2016 | 627 | 0.100 |
Why?
|
| Off-Label Use | 1 | 2014 | 185 | 0.100 |
Why?
|
| Follicular Phase | 1 | 2013 | 143 | 0.100 |
Why?
|
| Chicago | 1 | 2013 | 254 | 0.100 |
Why?
|
| Diagnosis, Differential | 6 | 2024 | 12974 | 0.100 |
Why?
|
| Mental Competency | 1 | 1993 | 176 | 0.100 |
Why?
|
| Universities | 3 | 2006 | 993 | 0.100 |
Why?
|
| Probability | 4 | 2002 | 2477 | 0.100 |
Why?
|
| Child | 5 | 2023 | 80153 | 0.100 |
Why?
|
| Agoraphobia | 2 | 1989 | 177 | 0.100 |
Why?
|
| Infant Behavior | 2 | 2011 | 156 | 0.100 |
Why?
|
| Umbilical Arteries | 1 | 1991 | 79 | 0.100 |
Why?
|
| Hyperbilirubinemia | 1 | 1991 | 74 | 0.090 |
Why?
|
| Hyperandrogenism | 3 | 2006 | 39 | 0.090 |
Why?
|
| Selection Bias | 1 | 2013 | 359 | 0.090 |
Why?
|
| Levonorgestrel | 1 | 2011 | 74 | 0.090 |
Why?
|
| S-Adenosylmethionine | 5 | 2010 | 218 | 0.090 |
Why?
|
| Abortion, Induced | 3 | 2004 | 462 | 0.090 |
Why?
|
| Tetralogy of Fallot | 1 | 2016 | 618 | 0.090 |
Why?
|
| Hypolipidemic Agents | 1 | 2015 | 609 | 0.090 |
Why?
|
| United States | 7 | 2021 | 72334 | 0.090 |
Why?
|
| Pregnancy, Ectopic | 1 | 2012 | 142 | 0.090 |
Why?
|
| Polycystic Ovary Syndrome | 2 | 2006 | 376 | 0.090 |
Why?
|
| Demography | 2 | 2008 | 1648 | 0.090 |
Why?
|
| Ear | 1 | 2011 | 172 | 0.090 |
Why?
|
| Male | 34 | 2018 | 360804 | 0.090 |
Why?
|
| Patient Selection | 4 | 2014 | 4244 | 0.090 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 2017 | 116 | 0.090 |
Why?
|
| Contraceptive Agents, Female | 1 | 2011 | 118 | 0.090 |
Why?
|
| Longitudinal Studies | 8 | 2018 | 14605 | 0.090 |
Why?
|
| Asymptomatic Diseases | 1 | 2013 | 588 | 0.080 |
Why?
|
| Attitude to Health | 2 | 2010 | 2025 | 0.080 |
Why?
|
| Trisomy | 1 | 2011 | 260 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2014 | 2281 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2015 | 2048 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2015 | 962 | 0.080 |
Why?
|
| Benzhydryl Compounds | 1 | 2016 | 916 | 0.080 |
Why?
|
| Fatigue | 2 | 2016 | 1552 | 0.080 |
Why?
|
| Child Behavior | 1 | 2014 | 847 | 0.080 |
Why?
|
| Liver Function Tests | 1 | 2010 | 523 | 0.080 |
Why?
|
| Abdomen | 1 | 1995 | 1128 | 0.080 |
Why?
|
| Folic Acid | 1 | 2015 | 1323 | 0.080 |
Why?
|
| Estriol | 1 | 2008 | 53 | 0.080 |
Why?
|
| Time Factors | 10 | 2014 | 39967 | 0.080 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2008 | 29 | 0.080 |
Why?
|
| Predictive Value of Tests | 7 | 2017 | 15266 | 0.080 |
Why?
|
| Reference Values | 3 | 2011 | 4920 | 0.080 |
Why?
|
| Abruptio Placentae | 1 | 1989 | 118 | 0.080 |
Why?
|
| Patient Satisfaction | 3 | 2014 | 3461 | 0.080 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 324 | 0.070 |
Why?
|
| Primary Ovarian Insufficiency | 2 | 2018 | 107 | 0.070 |
Why?
|
| Thyrotropin | 3 | 2007 | 834 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2011 | 916 | 0.070 |
Why?
|
| Complementary Therapies | 2 | 2010 | 486 | 0.070 |
Why?
|
| Alprazolam | 4 | 1993 | 102 | 0.070 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 1670 | 0.070 |
Why?
|
| Fetal Growth Retardation | 1 | 1991 | 580 | 0.070 |
Why?
|
| Triglycerides | 1 | 2015 | 2461 | 0.070 |
Why?
|
| Apgar Score | 3 | 2005 | 126 | 0.070 |
Why?
|
| Personality Inventory | 4 | 2009 | 1019 | 0.070 |
Why?
|
| Glycogen | 2 | 2018 | 251 | 0.070 |
Why?
|
| Students | 3 | 2006 | 1741 | 0.070 |
Why?
|
| Mental Health | 1 | 2021 | 3250 | 0.070 |
Why?
|
| Blood Urea Nitrogen | 1 | 2007 | 186 | 0.070 |
Why?
|
| Twins | 1 | 1988 | 339 | 0.070 |
Why?
|
| Medicaid | 2 | 2017 | 2818 | 0.070 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 3416 | 0.070 |
Why?
|
| Psychometrics | 1 | 2016 | 3065 | 0.070 |
Why?
|
| Twins, Monozygotic | 1 | 1988 | 470 | 0.070 |
Why?
|
| Norethindrone | 1 | 2006 | 56 | 0.070 |
Why?
|
| Patient Dropouts | 2 | 2007 | 412 | 0.070 |
Why?
|
| Lactobacillus | 2 | 2018 | 212 | 0.070 |
Why?
|
| Cocaine | 1 | 1991 | 958 | 0.070 |
Why?
|
| Robotics | 1 | 2013 | 819 | 0.070 |
Why?
|
| Diseases in Twins | 1 | 1988 | 446 | 0.070 |
Why?
|
| Dyspareunia | 2 | 2018 | 48 | 0.070 |
Why?
|
| Cholesterol | 1 | 2015 | 2904 | 0.070 |
Why?
|
| Ovariectomy | 2 | 2018 | 614 | 0.070 |
Why?
|
| Confusion | 1 | 2008 | 278 | 0.070 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 7045 | 0.070 |
Why?
|
| Delusions | 1 | 2008 | 298 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 4 | 2007 | 7390 | 0.070 |
Why?
|
| Oligomenorrhea | 1 | 2006 | 42 | 0.070 |
Why?
|
| Parity | 2 | 2007 | 927 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2017 | 3113 | 0.070 |
Why?
|
| Psychomotor Agitation | 1 | 2008 | 305 | 0.060 |
Why?
|
| Social Control Policies | 1 | 2005 | 9 | 0.060 |
Why?
|
| Menarche | 2 | 2006 | 532 | 0.060 |
Why?
|
| Preoperative Care | 1 | 1995 | 2242 | 0.060 |
Why?
|
| Student Health Services | 1 | 2005 | 40 | 0.060 |
Why?
|
| Brain | 4 | 2021 | 27112 | 0.060 |
Why?
|
| Haloperidol | 2 | 2002 | 389 | 0.060 |
Why?
|
| Metabolism | 1 | 2006 | 193 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 8654 | 0.060 |
Why?
|
| Urogenital Abnormalities | 1 | 2008 | 261 | 0.060 |
Why?
|
| Methotrexate | 1 | 2012 | 1719 | 0.060 |
Why?
|
| Risperidone | 2 | 2018 | 381 | 0.060 |
Why?
|
| Creatine | 1 | 2007 | 427 | 0.060 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 678 | 0.060 |
Why?
|
| Ganglionic Stimulants | 1 | 2004 | 18 | 0.060 |
Why?
|
| Sex Factors | 5 | 2005 | 10552 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2014 | 2180 | 0.060 |
Why?
|
| Abortifacient Agents, Steroidal | 1 | 2004 | 22 | 0.060 |
Why?
|
| Psychiatry | 2 | 2010 | 1693 | 0.060 |
Why?
|
| Heart Rate | 2 | 2015 | 4195 | 0.060 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 2164 | 0.060 |
Why?
|
| Embryonic and Fetal Development | 2 | 2004 | 420 | 0.060 |
Why?
|
| Logistic Models | 5 | 2014 | 13255 | 0.060 |
Why?
|
| Body Mass Index | 4 | 2017 | 12953 | 0.060 |
Why?
|
| Saliva | 1 | 2008 | 828 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2009 | 2078 | 0.050 |
Why?
|
| Ovarian Function Tests | 1 | 2003 | 11 | 0.050 |
Why?
|
| Hysterectomy | 2 | 2018 | 857 | 0.050 |
Why?
|
| Mifepristone | 1 | 2004 | 151 | 0.050 |
Why?
|
| Misoprostol | 1 | 2004 | 93 | 0.050 |
Why?
|
| Organizational Policy | 1 | 2005 | 432 | 0.050 |
Why?
|
| Amniocentesis | 2 | 2011 | 115 | 0.050 |
Why?
|
| Carbamazepine | 3 | 2004 | 224 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 2759 | 0.050 |
Why?
|
| Menstruation | 1 | 2004 | 307 | 0.050 |
Why?
|
| Amenorrhea | 1 | 2006 | 483 | 0.050 |
Why?
|
| Cytokines | 1 | 2017 | 7396 | 0.050 |
Why?
|
| Mianserin | 1 | 2001 | 51 | 0.050 |
Why?
|
| Asthma | 1 | 2021 | 6234 | 0.050 |
Why?
|
| Pirenzepine | 1 | 2002 | 116 | 0.050 |
Why?
|
| Neurology | 1 | 2010 | 780 | 0.050 |
Why?
|
| Uterine Hemorrhage | 1 | 2003 | 240 | 0.050 |
Why?
|
| Medical History Taking | 3 | 2017 | 774 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2007 | 10090 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2013 | 2035 | 0.050 |
Why?
|
| Dysthymic Disorder | 1 | 2001 | 75 | 0.050 |
Why?
|
| Epilepsy | 2 | 2010 | 3290 | 0.050 |
Why?
|
| Causality | 1 | 2007 | 1242 | 0.050 |
Why?
|
| Fetal Diseases | 3 | 2011 | 913 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2005 | 487 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2004 | 962 | 0.050 |
Why?
|
| Aged | 15 | 2020 | 169289 | 0.040 |
Why?
|
| Personality | 1 | 2004 | 554 | 0.040 |
Why?
|
| Hysterosalpingography | 1 | 2000 | 26 | 0.040 |
Why?
|
| Odds Ratio | 4 | 2009 | 9646 | 0.040 |
Why?
|
| Triazines | 2 | 2017 | 311 | 0.040 |
Why?
|
| Weight Gain | 1 | 2010 | 2348 | 0.040 |
Why?
|
| Smoking Cessation | 2 | 2009 | 2056 | 0.040 |
Why?
|
| Birth Weight | 2 | 2014 | 2103 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 12148 | 0.040 |
Why?
|
| Tranquilizing Agents | 1 | 1999 | 58 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2006 | 6343 | 0.040 |
Why?
|
| Ovulation | 1 | 2020 | 181 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 4243 | 0.040 |
Why?
|
| Pyridines | 1 | 2011 | 2875 | 0.040 |
Why?
|
| Nicotine | 1 | 2004 | 680 | 0.040 |
Why?
|
| Serotonin Agents | 1 | 1998 | 29 | 0.040 |
Why?
|
| Nervous System Malformations | 1 | 2001 | 244 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2001 | 957 | 0.040 |
Why?
|
| Somatoform Disorders | 1 | 2001 | 423 | 0.040 |
Why?
|
| Health Status | 2 | 2016 | 4077 | 0.040 |
Why?
|
| Abortion, Spontaneous | 1 | 2003 | 533 | 0.040 |
Why?
|
| Educational Status | 1 | 2006 | 2522 | 0.040 |
Why?
|
| Aggression | 1 | 2003 | 750 | 0.040 |
Why?
|
| Tobacco Use Disorder | 1 | 2004 | 703 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2014 | 3429 | 0.040 |
Why?
|
| Vulvar Diseases | 1 | 2018 | 64 | 0.040 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2017 | 45 | 0.040 |
Why?
|
| Prognosis | 5 | 2017 | 29625 | 0.040 |
Why?
|
| Boston | 3 | 2006 | 9326 | 0.040 |
Why?
|
| Tocolytic Agents | 1 | 1997 | 24 | 0.040 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2002 | 710 | 0.040 |
Why?
|
| Inflammation | 1 | 2017 | 10773 | 0.040 |
Why?
|
| Body Image | 1 | 2022 | 638 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2014 | 4811 | 0.040 |
Why?
|
| Magnesium Sulfate | 1 | 1997 | 73 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2003 | 1386 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2007 | 2979 | 0.030 |
Why?
|
| Indomethacin | 1 | 1997 | 325 | 0.030 |
Why?
|
| Blood Pressure | 4 | 2010 | 8481 | 0.030 |
Why?
|
| Estrone | 1 | 2017 | 234 | 0.030 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2020 | 357 | 0.030 |
Why?
|
| Placenta | 1 | 2005 | 1709 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2017 | 271 | 0.030 |
Why?
|
| Exercise Therapy | 2 | 2014 | 929 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 1998 | 249 | 0.030 |
Why?
|
| Chromosome Aberrations | 2 | 2011 | 1768 | 0.030 |
Why?
|
| Health Services Research | 1 | 2004 | 1812 | 0.030 |
Why?
|
| Motivation | 1 | 2006 | 2006 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2006 | 1936 | 0.030 |
Why?
|
| Teaching Materials | 1 | 2016 | 84 | 0.030 |
Why?
|
| Endosonography | 1 | 2000 | 609 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2010 | 3889 | 0.030 |
Why?
|
| Self Report | 2 | 2017 | 3724 | 0.030 |
Why?
|
| Delivery, Obstetric | 1 | 2002 | 940 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2001 | 879 | 0.030 |
Why?
|
| Translating | 1 | 2016 | 143 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2017 | 397 | 0.030 |
Why?
|
| Decision Making | 2 | 2002 | 3929 | 0.030 |
Why?
|
| Orgasm | 1 | 2014 | 61 | 0.030 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 1995 | 276 | 0.030 |
Why?
|
| Health Behavior | 1 | 2005 | 2643 | 0.030 |
Why?
|
| Urban Population | 1 | 2001 | 2036 | 0.030 |
Why?
|
| Ambulatory Care | 2 | 1994 | 2775 | 0.030 |
Why?
|
| Atrophy | 1 | 2018 | 1633 | 0.030 |
Why?
|
| Counseling | 1 | 2001 | 1547 | 0.030 |
Why?
|
| Tyrosine | 1 | 2017 | 1440 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2023 | 2629 | 0.030 |
Why?
|
| Research | 1 | 2021 | 1982 | 0.030 |
Why?
|
| Myocardial Infarction | 2 | 1988 | 11460 | 0.030 |
Why?
|
| Mental Health Services | 1 | 2024 | 1730 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2002 | 2690 | 0.020 |
Why?
|
| Pain | 1 | 2007 | 5073 | 0.020 |
Why?
|
| Choroid Plexus | 1 | 1994 | 240 | 0.020 |
Why?
|
| Papillary Muscles | 1 | 1972 | 192 | 0.020 |
Why?
|
| Quality Control | 1 | 2014 | 832 | 0.020 |
Why?
|
| Meditation | 1 | 2014 | 251 | 0.020 |
Why?
|
| Thiazoles | 1 | 2018 | 1517 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2024 | 42230 | 0.020 |
Why?
|
| Myocardial Contraction | 2 | 1993 | 1515 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2011 | 228 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2011 | 192 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2005 | 11121 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2011 | 247 | 0.020 |
Why?
|
| Disease Management | 1 | 2021 | 2508 | 0.020 |
Why?
|
| Radiography | 1 | 2001 | 6965 | 0.020 |
Why?
|
| Assertiveness | 1 | 2009 | 18 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 3205 | 0.020 |
Why?
|
| Endoscopy | 1 | 2000 | 1851 | 0.020 |
Why?
|
| Fetus | 1 | 1997 | 1863 | 0.020 |
Why?
|
| Neurotic Disorders | 1 | 2009 | 77 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2002 | 3600 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 14031 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2003 | 3979 | 0.020 |
Why?
|
| Cysts | 1 | 1994 | 681 | 0.020 |
Why?
|
| Receptors, Dopamine | 1 | 1990 | 296 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2016 | 2707 | 0.020 |
Why?
|
| Consensus | 1 | 2018 | 3123 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 1989 | 258 | 0.020 |
Why?
|
| Cervix Uteri | 1 | 2012 | 570 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 1991 | 1371 | 0.020 |
Why?
|
| Prolactin | 1 | 1990 | 625 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2003 | 1541 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 1779 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2005 | 4575 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2014 | 2358 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 1994 | 1265 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2001 | 7827 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 1988 | 329 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 841 | 0.020 |
Why?
|
| Informed Consent | 1 | 1993 | 1008 | 0.020 |
Why?
|
| Cardiac Output | 4 | 1993 | 831 | 0.020 |
Why?
|
| Hirsutism | 1 | 2006 | 68 | 0.020 |
Why?
|
| Propensity Score | 1 | 2014 | 1913 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2002 | 4686 | 0.020 |
Why?
|
| Administration, Oral | 5 | 1995 | 4021 | 0.020 |
Why?
|
| Exercise Test | 1 | 1993 | 2127 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1989 | 513 | 0.010 |
Why?
|
| Hydrocortisone | 2 | 1990 | 1819 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 1988 | 694 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 8708 | 0.010 |
Why?
|
| Texas | 1 | 2005 | 404 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 1988 | 959 | 0.010 |
Why?
|
| Angina, Unstable | 1 | 1988 | 888 | 0.010 |
Why?
|
| Arousal | 1 | 2009 | 1166 | 0.010 |
Why?
|
| Lithium Carbonate | 1 | 2004 | 179 | 0.010 |
Why?
|
| Schizophrenia | 1 | 2002 | 6937 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1993 | 4159 | 0.010 |
Why?
|
| Diet | 1 | 2001 | 8075 | 0.010 |
Why?
|
| Vascular Resistance | 2 | 1997 | 930 | 0.010 |
Why?
|
| Linear Models | 1 | 2012 | 5871 | 0.010 |
Why?
|
| Clinical Trials as Topic | 5 | 1990 | 8002 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2012 | 3550 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1988 | 1241 | 0.010 |
Why?
|
| Medroxyprogesterone | 1 | 2001 | 35 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1993 | 2521 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1997 | 2219 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1988 | 1787 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2002 | 311 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1993 | 3879 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 615 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 2 | 1990 | 139 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 5492 | 0.010 |
Why?
|
| Personality Assessment | 1 | 2001 | 650 | 0.010 |
Why?
|
| Occupations | 1 | 2002 | 515 | 0.010 |
Why?
|
| Length of Stay | 1 | 2013 | 6425 | 0.010 |
Why?
|
| Angiocardiography | 1 | 1979 | 149 | 0.010 |
Why?
|
| Sleep Deprivation | 1 | 2006 | 846 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 2880 | 0.010 |
Why?
|
| Fetal Blood | 1 | 2005 | 1347 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2008 | 2107 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2003 | 2927 | 0.010 |
Why?
|
| Labor, Obstetric | 1 | 2001 | 323 | 0.010 |
Why?
|
| Tocolysis | 1 | 1997 | 18 | 0.010 |
Why?
|
| Marital Status | 1 | 1999 | 426 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2006 | 36426 | 0.010 |
Why?
|
| Family Characteristics | 1 | 2002 | 1004 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2005 | 2495 | 0.010 |
Why?
|
| Community Health Services | 1 | 2001 | 656 | 0.010 |
Why?
|
| Coronary Disease | 3 | 1993 | 5914 | 0.010 |
Why?
|
| Connecticut | 1 | 1976 | 364 | 0.010 |
Why?
|
| Aspirin | 1 | 1988 | 3133 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2001 | 58976 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1979 | 667 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1988 | 2751 | 0.010 |
Why?
|
| Testosterone | 1 | 2006 | 2472 | 0.010 |
Why?
|
| Prefrontal Cortex | 1 | 2006 | 2219 | 0.010 |
Why?
|
| Social Support | 1 | 2005 | 2171 | 0.010 |
Why?
|
| Overweight | 1 | 2006 | 2417 | 0.010 |
Why?
|
| Heart | 1 | 1988 | 4404 | 0.010 |
Why?
|
| Death, Sudden | 1 | 1976 | 301 | 0.010 |
Why?
|
| Random Allocation | 2 | 1989 | 2395 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1997 | 1496 | 0.010 |
Why?
|
| Clomipramine | 1 | 1993 | 54 | 0.010 |
Why?
|
| Desipramine | 1 | 1993 | 182 | 0.010 |
Why?
|
| Age of Onset | 1 | 2000 | 3305 | 0.010 |
Why?
|
| Chordae Tendineae | 1 | 1972 | 39 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1988 | 4812 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2002 | 2093 | 0.010 |
Why?
|
| Chromosome Disorders | 1 | 1994 | 497 | 0.010 |
Why?
|
| Systole | 1 | 1993 | 936 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 11076 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 4618 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1988 | 1972 | 0.010 |
Why?
|
| Hypertension | 2 | 1989 | 8540 | 0.010 |
Why?
|
| Ataxia | 1 | 1991 | 306 | 0.000 |
Why?
|
| Autopsy | 1 | 1972 | 1008 | 0.000 |
Why?
|
| Protein-Losing Enteropathies | 1 | 1968 | 45 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17904 | 0.000 |
Why?
|
| Leukopenia | 1 | 1968 | 213 | 0.000 |
Why?
|
| Stroke Volume | 2 | 1993 | 5496 | 0.000 |
Why?
|
| Cerebral Hemorrhage | 1 | 1997 | 2656 | 0.000 |
Why?
|
| Brain Diseases | 1 | 1994 | 1545 | 0.000 |
Why?
|
| Heart Ventricles | 2 | 1979 | 3807 | 0.000 |
Why?
|
| Heart Valve Diseases | 1 | 1972 | 1027 | 0.000 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 1968 | 353 | 0.000 |
Why?
|
| Myocardium | 1 | 1976 | 4726 | 0.000 |
Why?
|
| Dexamethasone | 1 | 1990 | 1948 | 0.000 |
Why?
|
| Immunity | 1 | 1968 | 996 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 21012 | 0.000 |
Why?
|
| Animals | 1 | 1994 | 168459 | 0.000 |
Why?
|
| Coronary Vessels | 1 | 1972 | 3096 | 0.000 |
Why?
|
| Cardiomyopathies | 1 | 1972 | 1964 | 0.000 |
Why?
|
| Lymphocytes | 1 | 1968 | 2612 | 0.000 |
Why?
|
| Hospitalization | 1 | 1976 | 10723 | 0.000 |
Why?
|
| Chromium Isotopes | 1 | 1968 | 28 | 0.000 |
Why?
|
| Iodine Isotopes | 1 | 1968 | 79 | 0.000 |
Why?
|
| Pericarditis, Constrictive | 1 | 1968 | 46 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1968 | 361 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1968 | 490 | 0.000 |
Why?
|
| Rheumatic Heart Disease | 1 | 1968 | 163 | 0.000 |
Why?
|
| Skin Tests | 1 | 1968 | 637 | 0.000 |
Why?
|
| Transplantation Immunology | 1 | 1968 | 532 | 0.000 |
Why?
|
| Albumins | 1 | 1968 | 575 | 0.000 |
Why?
|
| Electrocardiography | 1 | 1979 | 6377 | 0.000 |
Why?
|
| Serum Albumin | 1 | 1968 | 672 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1968 | 1596 | 0.000 |
Why?
|
| Skin Transplantation | 1 | 1968 | 1083 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1968 | 4806 | 0.000 |
Why?
|
| Proteins | 1 | 1968 | 6032 | 0.000 |
Why?
|